Clinical Trial Technology Editorial

  1. Online Recruitment & A Virtual Study Net 4,000 Participants For MAGENTA Trial 8/27/2020

    Stand Up To Cancer (SU2C) has been around for more than 10 years. The organization was founded to promote collaborative and innovative cancer research by bringing together the best and brightest minds in the industry. It's recent MAGENTA study recruited nearly 4,000 patients by using online tools and a virtual approach.

  2. How TissueTech Managed Growth, Virtual Trials, And Survived COVID-19 8/11/2020

    Since its inception in 1997, TissueTech has been a pioneer in the clinical application of human birth tissues. In July 2020 the company announced the initiation of the first of two Phase 3 clinical trials. To complete those trials, the company knew it had to grow its internal capabilities. It did so by investing heavily in the expansion of its clinical and manufacturing programs.

  3. Will Pharma Sustain Improved Reputation and Trust Beyond COVID-19? 8/5/2020

    Pharma’s reputation has been battered in recent years, and Americans have never had a lower view of their prescription providers. Unfortunately, this is not simply an image issue. This viewpoint most certainly contributes to the challenge pharma companies face in recruiting participants into their clinical studies. While the industry had seemed unable to shake its negative image, there is now reason to believe the attitude of the public is shifting. The main reason for the turnaround is, surprisingly, COVID-19.

  4. Industry Execs Expect Continued Growth In mHealth & Virtual Trials 7/30/2020

    Research firm Industry Standard Research recently asked 329 respondents from sponsor organizations to share their thoughts about a variety of current trends in the clinical development space. ISR analyzed responses by company size to understand how perspectives of respondents at large sponsors differ from those at non-large organizations.

  5. ADAPTABLE Study Shows The Potential Of Virtual Trials 7/21/2020

    DCRI and PCORI started the ADAPTABLE clinical trial to the effect of different aspirin doses on patients with heart disease. Now that the trial is winding down, it's success has also shown sponsor companies how to successfully navigate a large, virtual clinical trial.

  6. The Expanding Role Of Artificial Intelligence In Clinical Research 6/9/2020

    While protocols and standards in clinical research have become increasingly complex, slowing progress and increasing costs, companies from startups to Big Pharma are identifying opportunities to apply AI to enhance trial efficiency, patient enrollment, and outcomes targeting.

  7. COVID-19 & The Virtual Trial Rush: Front-Line Insights 5/19/2020

    The COVID-19 pandemic caught many sponsor companies and sites unprepared. Clinical trial participants were told to stay home for their own safety and to relieve the burden on site personnel. For companies that had millions invested in trials that required data from those patients, panic set in and the rush was on for new technology solutions.

  8. Move Virtual Trials From Aspiration To Reality In Today’s Environment 5/14/2020

    With the COVID-19 pandemic upon us, we are at a place where the business case is clear, the barriers to adoption are largely removed, and sites and participants alike have begun accepting virtual trials as not just an option but a must.

  9. Which New Technologies & Training Will Drive Advancements In Clinical Trials? 4/30/2020

    Many changes are taking place that are having an impact on the conduct of clinical trials. New tools such as risk-based monitoring, real-world evidence, and adaptive trials are helping to fix a process that many believe is fundamentally broken. At the same time, trials are becoming more complex and new guidelines are being placed on sponsors. What will all of this mean for the conduct of trials in 2020 and beyond?

  10. COVID-19 Presents Unique Challenges For Oncology Trials 4/28/2020

    With the COVID-19 pandemic hitting countries around the world, many sponsor companies and sites are scrambling to implement remote monitoring solutions to protect their patients while not disrupting the data collection process. Unfortunately, for oncology patients, some of these technologies are not an option.